Versartis reports confirmatory top-line two-year data from somavaratan study Versartis announced confirmatory two-year, top-line safety and efficacy data from its ongoing Extension Study of somavaratan in children with GHD. The Extension Study is a long-term safety study that was initiated in March 2014 as patients completed the Phase 1b/2a clinical trial evaluating somavaratan therapy in treatment-naive, pre-pubertal GHD children. 57 patients were in the Extension Study during the 12-24 month period and were included in the Year 2 analyses. The Extension Study continued to show that the safety profile of somavaratan is similar to daily growth hormone therapy. Over the full 24 months of treatment, there were no drug-related serious adverse events, or SAEs, and nearly all drug-related AEs were mild and transient. Somavaratan was well tolerated and the patient discontinuation rate at 24 months was in line with expectations for long-term clinical studies.